Tianjin Chase Sun Pharmaceutical (300026) filed its revenue and net profit grew 87.67 percent and 33.61 percent year-on-year to 224 million yuan and 43.14 million yuan in the first half for EPS of 0.29 yuan, reports p5w.net.
Revenue growth came mainly from a 118 million yuan (52.88-percent) contribution from Kangrentang. Gross margins of sales of its low-molecular weight heparin calcium injection rose 44.72 percent year-on-year due to lower material costs and a higher sale price.
Â
